Global Direct Lateral Interbody Fusion (DLIF) and eXtreme Lateral Interbody Fusion (XLIF) Implants Market – Industry Trends and Forecast to 2029

 Direct Lateral Interbody Fusion (DLIF) and eXtreme Lateral Interbody Fusion (XLIF) Implants Market Analysis and Size

Direct lateral interbody fusion is recommended for patients with spinal instability caused by degenerative conditions, deformities, or injuries. Back pain, leg pain, or muscle weakness can result from spinal instability putting pressure on the spinal cord or spinal nerves. These signs and symptoms can spread to the hips, buttocks, and legs.

Data Bridge Market Research analyses that the direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants market which is expected to grow at a healthy CAGR during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Direct Lateral Interbody Fusion (DLIF) and eXtreme Lateral Interbody Fusion (XLIF) Implants Market Scope and Segmentation      

Market Definition

The procedure known as minimally invasive extreme lateral interbody fusion (XLIF) is used to treat degenerative disc disease (DDD), degenerative spondylolisthesis and degenerative scoliosis. Unlike most mid to low back spine surgery, which involves the large muscles in the middle of your back and avoiding large muscle groups.

Direct Lateral Interbody Fusion or DLIF, is a minimally invasive surgical procedure used to treat degenerative disc disease-related leg or back pain. Unlike traditional anterior or posterior approaches to back surgery, DLIF enters the lumbar spine from the side of the patient.

Global Direct Lateral Interbody Fusion (DLIF) and eXtreme Lateral Interbody Fusion (XLIF) Implants Market Dynamics

Drivers

• Rising usage of direct lateral interbody fusion

The direct lateral interbody fusion (DLIF), a minimally invasive lateral approach for placement of an interbody fusion device, does not require nerve root retraction or any contact with the great vessels and can lead to short operative times with little blood loss. This procedure has not been used at the lumbosacral (L5-S1) junction due to the anatomical restrictions. Lumbosacral transitional vertebrae (LSTV), a structural anomaly of the lumbosacral spine associated with low back pain, can result in a level being wrongly identified pre-operatively due to misnumbering of the vertebral levels. These are the certain factors which propel the growth of the market.

• Rising minimally invasive procedures

Extreme lateral interbody fusion (XLIF) is a minimally invasive procedure performed through the side of the body to treat spinal disorders and relieve chronic back or leg pain that has not responded to other treatments such as steroid injections, physical therapy, and pain medication. The minimally invasive extreme lateral interbody fusion (XLIF) procedure allows the doctor to avoid major large muscle groups in the centre of the back while removing the damaged disc. The muscles are not severed, rather they are separated gently to allow the spine surgeon access to the spine and the damaged disc. After removing the damaged disc, a small plastic cage filled with bone material is placed between the vertebrae. These are the factors which propel the growth of the market.

Opportunities

• Rising R&D activities

Rising R&D activities for spine surgery that is XLIF, which typically takes about an hour and performed under general anesthesia, the surgeon accesses the space between each spinal disc from the patient's side, rather than the front or back, sparing major back muscles, bones, and ligaments. It will provide ample opportunities for the growth of the direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants market during the forecast period.

Restraints/Challenges

• High cost of surgery

Unfavourable reimbursement policies of the insurance companies along with high cost of surgery and rising preferences of drugs over treatment which will acting as market restraints for the growth of the direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants in the above mentioned forecast period.

This direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Direct Lateral Interbody Fusion (DLIF) and eXtreme Lateral Interbody Fusion (XLIF) Implants Market Scope

The direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants market is segmented on the basis of indication and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Degenerative Disc Diseases
• Spondylolisthesis
• Scoliosis
• Others

  End User

• Ambulatory Surgical Units
• Hospitals
• Clinics
• Others

Direct Lateral Interbody Fusion (DLIF) and eXtreme Lateral Interbody Fusion (XLIF) Implants Market Regional Analysis/Insights

The direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants market is analysed and market size insights and trends are provided by country, indication and end user as referenced above.

The countries covered in the direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants market due to due to the growing occurrences of spinal injuries along with improved healthcare facilities and prevalence of geriatric population.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 owing to rising popularity of medial tourism and the development of improved infrastructure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants market. The data is available for historic period 2010-2020.

Competitive Landscape and Direct Lateral Interbody Fusion (DLIF) and eXtreme Lateral Interbody Fusion (XLIF) Implants Market Share Analysis

The direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants market.

Some of the major players operating in the direct lateral interbody fusion (DLIF) and eXtreme lateral interbody fusion (XLIF) implants market are:

• Medtronic (Ireland)
• NuVasive, Inc. (U.S.)
• Stryker (U.S.)
• Medical Devices Business Services, Inc. (U.S.)
• Zimmer Biomet (U.S.)
• Globus Medical (U.S.)
• Orthofix US LLC. (U.S.)
• ATech Spine, Inc. (U.S.)
• Osseous Surgicals (India)
• Captiva Spine, Inc. (U.S.)
• S. H. Pitkar Orthotools Pvt. Ltd. (India)
• Gesco Healthcare Pvt. Ltd. (India)
• Sharma Orthopedic (India)
• Jayon Implants (India)
• Implants International (U.K.)

SKU-55693